Wound healing ointment and preparation method thereof
Through the formula of water-in-oil cream and supercritical extraction technology, a wound healing cream suitable for burn and scald wounds was prepared, which solved the problem of insufficient breathability and hygroscopicity of the existing cream, significantly improved the healing effect of burn and scald wounds and Reduces the risk of infection.
Patent Information
- Application Number
- CN202411198853.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-08-29
AI Technical Summary
The existing wound healing cream has a single ingredients, poor breathability and hygroscopicity, resulting in slow healing speed of burns and scalds, high risk of scar formation and infection, and is expensive and has side effects.
Use water-in-oil cream formula, including Sipan 83, glyceryl monostearate, calcium stearate, white petroleum, paraffin, glycerol, hydroxybenzene and wound healing components (Taoyama White Extract, Juniper Leaf extract, ephedra extract, cypress branch extract, Artemisia delta extract), high-purity extract was obtained through supercritical carbon dioxide extraction, and paste was prepared in combination with stirring and heating.
It significantly improves the healing effect of burn and scald wounds, enhances breathability and hygroscopicity, reduces the risk of infection, has good product stability, is suitable for burn and scald wound healing, and improves the efficacy of the medicine by improving purity and extraction rate.
Smart Images

Figure CN118697781B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of scald ointments, and in particular to a wound healing ointment and a preparation method thereof. Background Art
[0002] In the biomedical field, wound healing has always been a hot topic and a difficult point of research. Currently, wound healing technologies mainly rely on traditional dressings and growth factors. Although these methods have achieved certain results in promoting wound healing, traditional dressings have poor air permeability and moisture absorption, which can easily lead to wound infection. Although the application of growth factors can promote cell proliferation, it is costly and has certain side effects. Moreover, traditional dressings and growth factors still have problems such as slow healing speed, scar formation, and high risk of infection in the treatment of wound healing.
[0003] Wound healing cream, as a pharmaceutical preparation directly applied to the wound, has the advantages of being easy to use and having a direct effect. However, most of the existing wound healing creams on the market have problems such as a single ingredient and poor effect, and cannot meet clinical needs. Therefore, a wound healing cream and a preparation method thereof are urgently needed to improve the therapeutic effect of burns and scalds. Summary of the invention
[0004] In order to solve the above technical problems, the present invention provides a wound healing ointment, which comprises, by mass ratio: 4-5 parts of Span 83, 5-7 parts of glyceryl monostearate, 2-4 parts of calcium stearate, 1-2 parts of aluminum distearate, 15-25 parts of white vaseline, 8-12 parts of No. 26 white beeswax, 2.5-3.5 parts of paraffin, 10-14 parts of glycerin, 0.08-0.12 parts of methylparaben, 4-6 parts of wound healing components, and 33-37 parts of water;
[0005] The wound healing ointment is a water-in-oil type cream;
[0006] The wound healing component comprises: 1 part of Rhizoma Cynanchum extract, 1 part of Juniperus chinensis leaf extract, 2 parts of Ephedra sinica extract, 2 parts of Cypress twig extract, and 3 parts of Artemisia annua extract;
[0007] The preparation method of the scutellaria baicalensis extract / juniper leaf extract / ephedra extract / water cypress branch extract / artemisia argyi extract is as follows:
[0008] Step 1, grinding the medicinal materials of Rhizoma Dioscoreae / Juniperus chinensis leaves / Ephedra sinica / Polygyna twigs / Artemisia scoparia with a grinder to obtain Rhizoma Dioscoreae powder / Juniperus chinensis leaves powder / Ephedra sinica powder / Polygyna twigs powder / Artemisia scoparia powder respectively;
[0009] Step 2, loading the scutellaria baicalensis powder / juniper leaf powder / ephedra powder / water cypress branch powder / artemisia scoparia powder into a supercritical extractor;
[0010] Step 3, pumping the carbon dioxide liquid into a supercritical extractor, extracting for 80-120 min, and obtaining supercritical carbon dioxide containing safflower, supercritical carbon dioxide containing juniper leaves, supercritical carbon dioxide containing ephedra, supercritical carbon dioxide containing cypress branches, and supercritical carbon dioxide containing wormwood;
[0011] Step 4, introducing the supercritical carbon dioxide containing Rhizoma Dioscoreae / supercritical carbon dioxide containing Juniperus chinensis leaves / supercritical carbon dioxide containing Ephedra sinica / supercritical carbon dioxide containing Cypress twigs / supercritical carbon dioxide containing Artemisia serrata into a separator, and separating the Rhizoma Dioscoreae extract / Juniperus chinensis leaves extract / Ephedra sinica extract / Cypress twigs extract / Artemisia serrata extract respectively.
[0012] Preferably, a wound healing cream comprises, by mass ratio: 4 parts of Span 83, 5 parts of glyceryl monostearate, 2 parts of calcium stearate, 1 part of aluminum distearate, 15 parts of white vaseline, 8 parts of No. 26 white beeswax, 2.5 parts of paraffin, 10 parts of glycerin, 0.08 parts of methylparaben, 4 parts of wound healing components, and 33 parts of water.
[0013] Preferably, a wound healing cream comprises, by mass ratio: 5 parts of Span 83, 7 parts of glyceryl monostearate, 4 parts of calcium stearate, 2 parts of aluminum distearate, 25 parts of white vaseline, 12 parts of No. 26 white beeswax, 3.5 parts of paraffin, 14 parts of glycerin, 0.12 parts of methylparaben, 6 parts of wound healing components, and 37 parts of water.
[0014] Preferably, a wound healing cream comprises, by mass ratio: 4.5 parts of Span 83, 6 parts of glyceryl monostearate, 3 parts of calcium stearate, 1.5 parts of aluminum distearate, 20 parts of white vaseline, 10 parts of No. 26 white beeswax, 3 parts of paraffin, 12 parts of glycerin, 0.1 parts of methylparaben, 5 parts of wound healing components, and 35 parts of water.
[0015] And, the preparation method of described wound healing ointment is as follows:
[0016] S1, adding methylparaben to glycerol, heating and stirring until dissolved, to obtain a methylparaben glycerol solution for later use;
[0017] S2, adding 4-6 parts of the wound healing component into water at a solid-liquid ratio of 1:6-8, stirring and dissolving to obtain an aqueous solution of the wound healing component for later use;
[0018] S3, mixing the methylparaben glycerol solution obtained in step S1 and the wound healing component aqueous solution obtained in step S2, stirring, heating to 75-85° C., and keeping warm for 10-20 minutes to obtain an aqueous phase drug;
[0019] S4, mixing Span 83, glyceryl monostearate, calcium stearate, aluminum distearate, white vaseline, No. 26 white beeswax, and paraffin, stirring, heating to 75-85° C., and keeping warm for 10-20 minutes to obtain an oil phase drug;
[0020] S5. Slowly add the water phase drug to the oil phase drug while stirring at 550-650 r / min. After adding, stir at 1000-1400 r / min for 10-20 min, then at 150-250 r / min for 4-6 min. Cool to 35-45°C, and stir at 3000-4000 r / min for 2-4 min to obtain a wound healing ointment.
[0021] Preferably, in a wound healing ointment, the temperature in step S1 is heated to 65-75°C.
[0022] Preferably, in a wound healing cream, in step S2, the wound healing component is added into water at a solid-liquid ratio of 1:7 and stirred to dissolve, so as to obtain an aqueous solution of the wound healing component.
[0023] Preferably, in a wound healing ointment, in step S5, the flow rate at which the aqueous phase drug is slowly added to the oil phase drug is 25-35 ml / min.
[0024] Compared with the prior art, the present invention has the following beneficial effects:
[0025] 1. The present invention provides a wound healing cream and a preparation method thereof. The wound healing cream is of a water-in-oil type, which is more suitable for burn and scald wounds. The product has a uniform appearance, a fine paste, good stability, a pH value of 6.0-7.0, does not irritate the skin, has good spreadability and moisturizing properties, and contains wound healing components (active ingredients of Rhizoma Dioscoreae extract, Juniperus chinensis leaf extract, Ephedra sinica extract, Cypress twig extract, and Artemisia annua extract), can promote the healing of burn and scald wounds, can prevent infection after covering the wound, has good air permeability, is simple in preparation process, and is easy to produce.
[0026] 2. The present invention adopts wound healing components (active ingredients of Rhizoma Atractylodis Macrocephalae extract, Juniperus chinensis leaf extract, Ephedra sinica extract, Cypress twig extract, and Artemisia annua extract) as the main components of the wound healing cream, which can quickly promote wound healing and significantly improve the wound healing effect; the wound healing cream of the present invention is an oil-in-water cream with good air permeability and hygroscopicity, which can effectively reduce the risk of wound infection and is particularly suitable for the healing of burn and scald wounds; the present invention also adopts an advanced preparation process to ensure the stability and safety of the product.
[0027] 3. The Rhizoma Dioscoreae extract, Juniperus chinensis leaf extract, Ephedra sinica extract, Rhizoma Cyperi twig extract, and Artemisia annua extract used in the present invention are obtained by CO2 supercritical extraction, which can not only achieve a higher extraction rate in a shorter time, but also obtain high-purity medicinal material extracts, reduce impurity content, improve product quality, and further improve the efficacy of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 Pathological staining results of each treatment group;
[0029] Figure 2 The immunohistochemical staining results of CD31 and ITGA6 in each treatment group;
[0030] Figure 3 Comparison of the wound healing ointments prepared in Example 3, Comparative Example 2 and Comparative Example 3. DETAILED DESCRIPTION
[0031] Example 1
[0032] A wound healing ointment, comprising, by mass ratio: 4 parts of Span 83, 5 parts of glyceryl monostearate, 2 parts of calcium stearate, 1 part of aluminum distearate, 15 parts of white vaseline, 8 parts of No. 26 white beeswax, 2.5 parts of paraffin, 10 parts of glycerin, 0.08 parts of methylparaben, 4 parts of wound healing components, and 33 parts of water;
[0033] The wound healing ointment is a water-in-oil type cream;
[0034] The wound healing component comprises: 1 part of Rhizoma Cynanchum extract, 1 part of Juniperus chinensis leaf extract, 2 parts of Ephedra sinica extract, 2 parts of Cypress twig extract, and 3 parts of Artemisia annua extract;
[0035] The preparation method of the scutellaria baicalensis extract / juniper leaf extract / ephedra extract / water cypress branch extract / artemisia argyi extract is as follows:
[0036] Step 1, grinding the medicinal materials of Rhizoma Dioscoreae / Juniperus chinensis leaves / Ephedra sinica / Polygyna twigs / Artemisia scoparia with a grinder to obtain Rhizoma Dioscoreae powder / Juniperus chinensis leaves powder / Ephedra sinica powder / Polygyna twigs powder / Artemisia scoparia powder respectively;
[0037] Step 2, loading the scutellaria baicalensis powder / juniper leaf powder / ephedra powder / water cypress branch powder / artemisia scoparia powder into a supercritical extractor;
[0038] Step 3, pumping the carbon dioxide liquid into a supercritical extractor, extracting for 100 minutes, and obtaining supercritical carbon dioxide containing safflower, supercritical carbon dioxide containing juniper leaves, supercritical carbon dioxide containing ephedra, supercritical carbon dioxide containing cypress branches, and supercritical carbon dioxide containing wormwood;
[0039] Step 4, introducing the supercritical carbon dioxide containing Rhizoma Dioscoreae / supercritical carbon dioxide containing Juniperus chinensis leaves / supercritical carbon dioxide containing Ephedra sinica / supercritical carbon dioxide containing Cypress twigs / supercritical carbon dioxide containing Artemisia serrata into a separator, and separating the Rhizoma Dioscoreae extract / Juniperus chinensis leaves extract / Ephedra sinica extract / Cypress twigs extract / Artemisia serrata extract respectively.
[0040] And, the preparation method of described wound healing ointment is as follows:
[0041] S1, adding methylparaben to glycerol, heating and stirring until dissolved, to obtain a methylparaben glycerol solution for later use;
[0042] S2, adding 4 parts of wound healing components into water at a solid-liquid ratio of 1:6, stirring and dissolving to obtain an aqueous solution of wound healing components for later use;
[0043] S3, mixing the methylparaben glycerol solution obtained in step S1 and the wound healing component aqueous solution obtained in step S2, stirring, heating to 75° C., and keeping warm for 10 minutes to obtain an aqueous phase drug;
[0044] S4, mixing Span 83, glyceryl monostearate, calcium stearate, aluminum distearate, white vaseline, No. 26 white beeswax and paraffin, stirring, heating to 75° C., and keeping warm for 10 min to obtain an oil phase drug;
[0045] S5. Slowly add the water phase drug to the oil phase drug under stirring at 550 r / min. After the addition is completed, stir at 1000 r / min for 10 min, then at 150 r / min for 4 min. Cool to 35°C, and stir at 3000 r / min for 2 min to obtain a wound healing ointment.
[0046] Preferably, in a wound healing ointment, the heating in step S1 is performed at 65°C.
[0047] Preferably, in a wound healing ointment, in step S5, the flow rate at which the water phase drug is slowly added to the oil phase drug is 25 ml / min.
[0048] Example 2
[0049] A wound healing ointment, comprising, by weight ratio: 5 parts of Span 83, 7 parts of glyceryl monostearate, 4 parts of calcium stearate, 2 parts of aluminum distearate, 25 parts of white vaseline, 12 parts of No. 26 white beeswax, 3.5 parts of paraffin, 14 parts of glycerin, 0.12 parts of methylparaben, 6 parts of wound healing components, and 37 parts of water;
[0050] The wound healing component comprises: 1 part of Rhizoma Cynanchum extract, 1 part of Juniperus chinensis leaf extract, 2 parts of Ephedra sinica extract, 2 parts of Cypress twig extract, and 3 parts of Artemisia annua extract;
[0051] The wound healing ointment is a water-in-oil type cream;
[0052] The preparation method of the genus Artemisia selengensis extract / juniper leaf extract / ephedra extract / water cypress branch extract / artemisia argyi extract is the same as that of Example 1.
[0053] And, the preparation method of described wound healing ointment is as follows:
[0054] S1, adding methylparaben to glycerol, heating and stirring until dissolved, to obtain a methylparaben glycerol solution for later use;
[0055] S2, adding the wound healing component into water at a solid-liquid ratio of 1:8, stirring and dissolving to obtain an aqueous solution of the wound healing component for later use;
[0056] S3, mixing the methylparaben glycerol solution obtained in step S1 and the wound healing component aqueous solution obtained in step S2, stirring, heating to 85° C., and keeping warm for 20 minutes to obtain an aqueous phase drug;
[0057] S4, mixing Span 83, glyceryl monostearate, calcium stearate, aluminum distearate, white vaseline, No. 26 white beeswax and paraffin, stirring, heating to 85° C., and keeping warm for 20 min to obtain an oil phase drug;
[0058] S5. Slowly add the water phase drug to the oil phase drug under stirring at 650 r / min. After the addition is completed, stir at 1400 r / min for 20 min, 50 r / min for 6 min, cool to 45°C, and stir at 4000 r / min for 4 min to obtain the wound healing ointment.
[0059] Preferably, in a wound healing ointment, the heating in step S1 is performed at 75°C.
[0060] Preferably, in a wound healing ointment, in step S5, the flow rate at which the water phase drug is slowly added to the oil phase drug is 35 ml / min.
[0061] Example 3
[0062] A wound healing ointment, comprising, by weight ratio: 4.5 parts of Span 83, 6 parts of glyceryl monostearate, 3 parts of calcium stearate, 1.5 parts of aluminum distearate, 20 parts of white vaseline, 10 parts of No. 26 white beeswax, 3 parts of paraffin, 12 parts of glycerin, 0.1 parts of methylparaben, 5 parts of wound healing components, and 33-37 parts of water;
[0063] The wound healing ointment is a water-in-oil type cream;
[0064] The wound healing component comprises: 1 part of Rhizoma Cynanchum extract, 1 part of Juniperus chinensis leaf extract, 2 parts of Ephedra sinica extract, 2 parts of Cypress twig extract, and 3 parts of Artemisia annua extract;
[0065] The preparation method of the genus Artemisia selengensis extract / juniper leaf extract / ephedra extract / water cypress branch extract / artemisia argyi extract is the same as that of Example 1.
[0066] And, the preparation method of described wound healing ointment is as follows:
[0067] S1, adding methylparaben to glycerol, heating and stirring until dissolved, to obtain a methylparaben glycerol solution for later use;
[0068] S2, adding the wound healing component into water at a solid-liquid ratio of 1:7, stirring and dissolving to obtain an aqueous solution of the wound healing component for later use;
[0069] S3, mixing the methylparaben glycerol solution obtained in step S1 and the wound healing component aqueous solution obtained in step S2, stirring, heating to 80° C., and keeping warm for 15 minutes to obtain an aqueous phase drug;
[0070] S4, mixing Span 83, glyceryl monostearate, calcium stearate, aluminum distearate, white vaseline, No. 26 white beeswax, and paraffin, stirring, heating to 80° C., and keeping warm for 15 min to obtain an oil phase drug;
[0071] S5. Slowly add the water phase drug to the oil phase drug under stirring at 600 r / min. After the addition is completed, stir at 1200 r / min for 15 min, stir at 200 r / min for 5 min, cool to 40°C, and stir at 3500 r / min for 4 min to obtain the wound healing ointment.
[0072] Preferably, in a wound healing ointment, the heating in step S1 is performed at 70°C.
[0073] Preferably, in a wound healing ointment, in step S5, the flow rate at which the water phase drug is slowly added to the oil phase drug is 30 ml / min.
[0074] Comparative Example 1
[0075] The difference between this comparative example and Example 3 is that: the wound healing component is not added to the wound healing ointment;
[0076] The preparation method of described wound healing ointment is as follows:
[0077] S1, adding methylparaben to glycerol, heating and stirring until dissolved, to obtain a methylparaben glycerol solution for later use;
[0078] S2, mixing Span 83, glyceryl monostearate, calcium stearate, aluminum distearate, white vaseline, No. 26 white beeswax, and paraffin, stirring, heating to 85° C., and keeping warm for 20 min to obtain an oil phase drug;
[0079] S3. Slowly add the glycerol solution into the oil phase medicine while stirring at 650 r / min. After the addition is completed, stir at 1400 r / min for 20 min, then at 250 r / min for 6 min. Cool to 45°C, and stir at 4000 r / min for 4 min to obtain a wound healing ointment.
[0080] Furthermore, the heating is performed at 75° C. in the step S1.
[0081] Moreover, in step S3, the flow rate at which the aqueous phase drug is slowly added to the oil phase drug is 35 ml / min.
[0082] Comparative Example 2
[0083] The difference between this comparative example and Example 3 is that the added amount of Span 83 is 2 parts.
[0084] Comparative Example 3
[0085] The difference between this comparative example and Example 3 is that the added amount of Span 83 is 8 parts.
[0086] Experimental Section
[0087] Experiment 1
[0088] The wound healing ointments prepared in Example 3, Comparative Examples 2 and 3 were observed and photographed. Figure 3 As can be seen from the figure, the water-in-oil type obtained by the technical solution of the present invention has a moderate consistency and is more suitable for burn wounds. However, in Comparative Examples 2 and 3, due to the large / small amount of Span 83 added, the morphology of the wound healing ointment is affected, and it cannot be maintained on the wound for a long time, affecting the treatment effect.
[0089] Experiment 2
[0090] The wound healing ointment prepared in Example 3 was tested as follows:
[0091] 1. Appearance
[0092] The appearance evaluation was carried out in accordance with the provisions of 5.1.1 Appearance of "QB / T1857-2013 Moisturizing Creams", and the wound healing cream was delicate, uniform and consistent.
[0093] 2. pH
[0094] Sample pretreatment: weigh 2 g of wound healing ointment sample (accurate to 0.1 g), place it in a 25 ml colorimetric tube, add 5 ml of water, vortex mix for 30 seconds, add 15 ml of water, shake gently to mix, ultrasonicate in an 80 ° C water bath for 30 minutes, cool to room temperature, centrifuge at 10000 r / min for 20 minutes, and take 15 ml of the supernatant as the test solution;
[0095] Determination: The pH value determination method was used in accordance with Part IV 0631 of the 2020 edition of the "Chinese Pharmacopoeia". The test result was 6.74, which met the requirements of "pH5-7".
[0096] 3. Stability
[0097] Heat resistance: The heat resistance test was carried out in accordance with the provisions of 5.2.3 Heat resistance (W / O) of "QB / T1857-2013 Moisturizing Cream", maintaining at (40±1)℃ for 24 hours. After returning to room temperature, the oil penetration rate was detected to be 2.12%, which meets the requirement of "the oil penetration rate should not be greater than 3%".
[0098] Cold resistance: The cold resistance test was carried out in accordance with the provisions of Item 5.2.4 of "QB / T1857-2013 Moisturizing Cream", (-8±2)℃ was maintained for 24 hours. After returning to room temperature, there was no obvious difference in properties compared with before the experiment, which met the requirements.
[0099] Experiment 3
[0100] 1. Modeling:
[0101] Establishment of deep second-degree burn model: 40 Kunming mice were selected. After one week of adaptive feeding, the hair on both sides of the spine of the back was removed with depilatory cream, and 10% chloral hydrate (400 mg / kg) was injected intraperitoneally for anesthesia. After disinfection with 75% alcohol, the cut surface was 2 cm 2 A copper cylinder was heated in a 95 ℃ constant temperature water bath for 10 min, then quickly taken out of the water bath and placed in contact with the skin for 10 s under gravity to produce a burn wound.
[0102] 2. Grouping: The 40 Kunming mice were divided into 2 equal parts, each with 20 mice. The 20 Kunming mice in each part were then divided into 4 groups: a control group (room temperature copper cylinder contact), a model group (Comparative Example 1), a positive drug group (moist burn ointment), and a treatment group (Example 3), each with 5 mice.
[0103] Dosage method: Drug administration began on the first day of scald, and each group was sprayed with lysozyme spray to prevent infection. The wound healing ointment of the above groups was applied for intervention once a day for three consecutive weeks. Each group was kept separately at room temperature and had free access to food, water, and defecation.
[0104] 3. Index determination:
[0105] (1) Determination of wound healing rate:
[0106] One group of Kunming mice was randomly selected, and after the burn wound was made, the mice in each group were measured on the 1st, 2nd, 3rd, 5th, 7th and 14th day after the wound was made by the tracing and weighing method: transparent grid paper was spread on the scald area, and the wound area at the corresponding time was traced. The wound was cut according to the traced handwriting and weighed, and the weight of the cut paper was used instead of the area. The wound area on the 2nd day after the wound was made was taken as the scald area, and the area measured at other times was the area at each time point. The wound healing rate was calculated, and the wound healing rate (%) = (original scald area-area at each time point) / scald area × 100%. The results are shown in Table 1.
[0107] Table 1 Wound healing rate
[0108]
[0109] As can be seen from Table 1, on the first day after deep II degree scald, there was no significant difference in wound healing rates among the model group, the positive drug group and the treatment group; on the 2nd, 3rd, 5th, 7th and 14th days after deep II degree scald, the wound healing rates of the positive drug group and the treatment group were significantly improved compared with the model group, and the differences were statistically significant (*P<0.05, **P<0.01), indicating that the wound healing ointment provided by the present invention can effectively promote the healing of deep II degree scald wounds, and the effect is similar to that of commercially available moist burn ointment.
[0110] (2) Pathological staining:
[0111] Another group of Kunming mice was taken and grouped, modeled, and administered in the same manner as above. On the 7th day of administration, blood was collected from the abdominal aorta, and all mice were anesthetized and killed. Part of the skin at the wound site was fixed in 4% formaldehyde, embedded in paraffin, cut into 4 μm sections, stained with HE, and observed and photographed under a microscope. Figure 1 As shown, from Figure 1 It can be seen that:
[0112] Control group: The epidermal structure of the skin tissue was intact, the stratum corneum was hyperkeratotic, the dermis was thickened, the collagen fibers were rich and neatly arranged, and the skin appendages, hair follicles and sebaceous glands were scattered; the subcutaneous tissue was located below the dermis and was composed of loose connective tissue, adipose tissue and muscle layer; no obvious inflammatory changes were observed.
[0113] Model group: large areas of necrosis were observed in the epidermis and superficial dermis of the skin tissue, eosinophilic homogeneous necrotic material and inflammatory exudate were observed, the stratum corneum was hyperkeratotic, the epidermis was slightly thickened, the prickle cells were proliferating, the nuclei of many prickle cells were wrinkled and darkly stained, the dermis was thickened, mild connective tissue hyperplasia was observed locally, small areas of edema were observed, the connective tissue was loosely arranged, a small number of new blood vessels were observed, and a small number of lymphocytes were scattered infiltrates.
[0114] Treatment group: The epidermis of the skin tissue was intact, with a small amount of vacuolar degeneration of spinous cells visible in the epidermis; the dermis was thickened, with rich and neatly arranged collagen fibers, and scattered distribution of skin appendages, hair follicles, and sebaceous glands; the subcutaneous tissue was located below the dermis, and was composed of loose connective tissue, adipose tissue, and muscle layer; no obvious inflammatory changes were observed.
[0115] Positive drug group: The epidermal structure of skin tissue was intact, the stratum corneum was hyperkeratotic, the epidermis was slightly thickened, the spinous cells were hyperplastic, a small number of spinous cells had vacuolar degeneration, the dermis was thickened, and mild hyperplasia of connective tissue was visible in the superficial dermis. The number of skin appendages was slightly reduced, and a small number of scattered lymphocytes were visible.
[0116] The above results indicate that the wound healing cream provided by the present invention has a positive effect on the recovery of deep second degree burn skin and the maintenance of its structural integrity.
[0117] (3) Determination of serum inflammatory factors TNF-α, IFN-γ, IL-6 and IL-1β:
[0118] The abdominal aorta blood obtained in the above experiment was placed in a serum separation tube and centrifuged at 3000 r / min for 20 min. The supernatant was taken and tested using an ELISA kit. The results are shown in Table 2.
[0119] Table 2 Results of TNF-α, IFN-γ, IL-6 and IL-1β assays
[0120]
[0121] After a burn, a series of inflammatory responses are immediately initiated in the body to cope with tissue damage and begin the repair process. Serum inflammatory factors such as tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukin-6 (IL-6) and interleukin-1β (IL-1β) play a key role in this process.
[0122] TNF-α promotes inflammation, increases vascular permeability, and makes it easier for immune cells to reach damaged areas. TNF-α is an early mediator in the inflammatory response, and its excessive expression may lead to increased tissue damage.
[0123] IFN-γ activates macrophages, enhances antigen presentation, and promotes Th1 cell response. Its increase may also aggravate inflammatory response and tissue damage.
[0124] IL-6 has both pro-inflammatory and anti-inflammatory effects and is involved in the acute phase response. IL-6 is one of the fastest-reacting inflammatory factors in serum and can be used as a biomarker for the degree of inflammation.
[0125] IL-1β promotes the recruitment and activation of inflammatory cells and enhances the inflammatory response. IL-1β is rapidly released in the early stages after burns, and it can promote the production of other inflammatory mediators and accelerate the development of the inflammatory response.
[0126] The upregulation of inflammatory factors such as TNF-α, IFN-γ, IL-6 and IL-1β in various inflammatory and autoimmune conditions is closely related to the pathological state. As can be seen from Table 2, the significant increase in inflammatory factors in the model group reflects the successful establishment of the inflammatory model and the activation of the inflammatory process. The decrease in the level of inflammatory factors in the treatment group indicates that the wound healing ointment provided by the present invention can effectively inhibit the inflammatory response caused by deep second-degree burns, and its effect is equivalent to that of positive drugs.
[0127] (4) Determination of immune factors in skin tissue
[0128] Immunohistochemistry was used to determine CD31 and integrin ITGA6. CD31, also known as lamellae endothelial cell adhesion molecule-1 (PECAM-1), is mainly expressed on endothelial cells and plays an important role in angiogenesis and migration of endothelial cells. After burns, the body initiates repair mechanisms, including the formation of new blood vessels to promote the supply of oxygen and nutrients to damaged tissues.
[0129] As a marker of angiogenesis, increased expression of CD31 usually means enhanced vascular reconstruction activity, which helps to improve blood circulation and wound healing in the burned area.
[0130] ITGA6 is the abbreviation of integrin α6, which is a cell surface receptor that interacts with the extracellular matrix (such as laminin) to promote cell adhesion and migration. After skin injuries such as burns, the increased expression of ITGA6 helps the migration of epidermal cells and the formation of new skin. Integrin α6 plays a vital role in promoting the movement of epidermal cells to the wound area and accelerating the wound closure process.
[0131] The results are shown in Table 3 and Figure 2 As shown, Figure 2 In the figure, yellow represents positive cells (cells labeled by CD31 and ITGA6), and blue represents negative cells (cells not labeled by CD31 and ITGA6). Among them, labeling refers to successful staining, and cells labeled by CD31 and ITGA6 indicate that the cells contain CD31 and ITGA6 proteins.
[0132] Table 3 Results of determination of immune factors in skin tissue
[0133]
[0134] Figure 3The results of CD31 and ITGA6 in Table 3 show that the angiogenesis process and epidermal repair after burns were significantly activated, especially in the treatment group, the expression levels of CD31 and ITGA6 were significantly higher than those in the model group. This result shows that the wound healing ointment provided by the present invention has potential benefits in promoting angiogenesis and epidermal repair.
[0135] (5) Determination of skin tissue growth factors VEGF and EGF
[0136] The mouse skin sample was placed in a cell disruptor, tissue extraction buffer was added, and the tissue was thoroughly disrupted by mechanical methods to release the protein in the cells; the supernatant was centrifuged and collected, and diluted to an appropriate concentration range according to the recommendations of the kit, and detected using an ELISA kit, with total protein content as the internal reference. The results are shown in Table 4 below.
[0137] Table 4 VEGF and EGF determination results
[0138]
[0139] After burns, the repair and regeneration process of skin tissue is very complex, involving multiple cell types and growth factors. Vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) play a vital role in this process.
[0140] The main function of VEGF is to promote the formation of new blood vessels (angiogenesis), which is crucial for repair after burns. After tissue damage caused by burns, new blood vessels are needed to supply nutrients and oxygen, and at the same time help remove waste and debris from the damaged area. VEGF stimulates the proliferation and migration of nearby undamaged vascular endothelial cells to form a new vascular network, thereby supporting the repair and regeneration of damaged tissue; in addition, VEGF can also increase blood flow to damaged tissue areas by promoting vascular permeability, which helps in all stages of inflammatory response and wound healing.
[0141] EGF is a powerful cell proliferation and differentiation factor that mainly acts on the epidermis of the skin. After burns, EGF binds to specific receptors on the surface of epidermal cells to activate the signal pathways of cell proliferation and differentiation, thereby promoting the rapid regeneration of epidermal cells and wound closure. EGF can also promote the migration and proliferation of keratinocytes, accelerate the epidermalization process of wounds, and is a key factor in repairing damaged skin barrier function.
[0142] The expression levels of VEGF and EGF increased significantly after scalding, which is consistent with the role of the two growth factors in promoting wound healing, especially playing a key role in promoting new blood vessel formation and improving blood supply to damaged tissues, while promoting cell proliferation and differentiation. As can be seen from Table 4, the levels of VEGF and EGF in the treatment group were significantly higher than those in the model group, and even higher than those in the positive drug group, indicating that the wound healing component provided by the present invention can effectively promote the production of VEGF and EGF, thereby possibly accelerating the wound healing process.
[0143] (6) Determination of peroxidative damage in skin tissue
[0144] Malondialdehyde (MDA) is a highly active reactive lipid peroxidation product, which is often used as an indicator to measure the level of oxidative stress. Cell damage caused by burns can activate lipid peroxidation reactions and produce a large number of free radicals. These free radicals attack the unsaturated fatty acids in the cell membrane to generate MDA. Therefore, the increase in MDA levels after burns usually reflects the severity of cell membrane damage and the increase in oxidative stress. High levels of MDA may indicate increased tissue damage and potential obstacles in the healing process.
[0145] Superoxide dismutase (SOD) is an important antioxidant enzyme. Its main function is to catalyze the conversion of superoxide anions (a harmful free radical) into hydrogen peroxide (H2O2) and oxygen, thereby reducing oxidative stress. After burns, the activity of SOD usually increases. As an adaptive response of the body to enhanced oxidative stress, the increase in SOD activity helps control local inflammation and limit further damage caused by free radicals, which is essential for protecting tissues and promoting the wound healing process.
[0146] Myeloperoxidase (MPO) is an enzyme mainly produced by neutrophils. It is involved in the production of chlorine oxidants, such as hypochlorous acid, which play an important role in killing invading microorganisms and promoting inflammatory responses. After burns, increased MPO activity in tissues usually reflects the infiltration and activation of neutrophils and is a sign of local inflammatory response. Although MPO is necessary for the initial defense response, excessive MPO activity may cause further damage to surrounding healthy tissues, thereby affecting wound healing.
[0147] Skin tissue peroxidation damage malondialdehyde (MDA), superoxide dismutase (SOD), and myeloperoxidase (MPO) were determined using ELISA kits with total protein content as the internal reference. The results are shown in Table 5.
[0148] Table 5 Results of determination of skin tissue peroxidation damage
[0149]
[0150] MDA is a direct marker of lipid peroxidation, and its increased level reflects the damage to the cell membrane and the aggravation of oxidative stress. As can be seen from Table 5, scald significantly increased the MDA level, while the treatment group and the positive drug group significantly reduced the MDA content. The wound healing ointment provided by the present invention, like the positive drug group, can effectively reduce oxidative damage and protect cells from further damage.
[0151] SOD is an important antioxidant enzyme that can effectively remove superoxide free radicals, reduce oxidative stress, and protect cells from damage. As can be seen from Table 5, in the model group, the significant decrease in SOD activity indicates the aggravation of oxidative damage and the inhibition of the antioxidant defense system. The recovery of SOD activity in the treatment group and the positive drug group indicates that the wound healing cream and the positive drug group provided by the present invention are helpful to restore the activity of antioxidant enzymes and enhance the body's antioxidant capacity, thereby being expected to improve the tissue repair process after burns.
[0152] MPO is an enzyme enriched in neutrophils and is usually used as a marker of inflammation. Under pathological conditions, the increase in MPO activity usually reflects the aggravation of the inflammatory response and the increase in reactive oxygen species. As can be seen from Table 5, the MPO activity of the model group increased significantly, indicating that the inflammatory state has been successfully introduced, and the MPO activity of the treatment group and the positive drug group was lower than that of the model group, indicating that the wound healing ointment provided by the present invention can effectively control the inflammatory response, just like the positive drug group.
Claims
1. A wound healing ointment, characterized in that: According to the mass ratio, it includes: 4-5 parts of Span 83, 5-7 parts of glyceryl monostearate, 2-4 parts of calcium stearate, 1-2 parts of aluminum distearate, 15-25 parts of white vaseline, 8-12 parts of No. 26 white beeswax, 2.5-3.5 parts of paraffin, 10-14 parts of glycerin, 0.08-0.12 parts of methylparaben, 4-6 parts of wound healing components, and 33-37 parts of water; The wound healing component comprises: 1 part of Rhizoma Cynanchum extract, 1 part of Juniperus chinensis leaf extract, 2 parts of Ephedra sinica extract, 2 parts of Cypress twig extract, and 3 parts of Artemisia annua extract; The wound healing ointment is a water-in-oil type cream; The preparation method of the iris scabra extract / juniper leaf extract / ephedra extract / water cypress branch extract / artemisia scoparia extract is as follows: Step 1, grinding the medicinal materials of Rhizoma Dioscoreae / Juniperus chinensis leaves / Ephedra sinica / Polygyna twigs / Artemisia scoparia with a grinder to obtain Rhizoma Dioscoreae powder / Juniperus chinensis leaves powder / Ephedra sinica powder / Polygyna twigs powder / Artemisia scoparia powder respectively; Step 2, loading the scutellaria baicalensis powder / juniper leaf powder / ephedra powder / water cypress branch powder / artemisia scoparia powder into a supercritical extractor; Step 3, pumping the carbon dioxide liquid into a supercritical extractor, extracting for 80-120 min, and obtaining supercritical carbon dioxide containing safflower, supercritical carbon dioxide containing juniper leaves, supercritical carbon dioxide containing ephedra, supercritical carbon dioxide containing cypress branches, and supercritical carbon dioxide containing wormwood; Step 4, introducing the supercritical carbon dioxide containing Rhizoma Dioscoreae / supercritical carbon dioxide containing Juniperus chinensis leaves / supercritical carbon dioxide containing Ephedra sinica / supercritical carbon dioxide containing Cypress twigs / supercritical carbon dioxide containing Artemisia serrata into a separator, and separating the Rhizoma Dioscoreae extract / Juniperus chinensis leaves extract / Ephedra sinica extract / Cypress twigs extract / Artemisia serrata extract respectively.
2. A wound healing ointment as claimed in claim 1, characterized in that, The mixture is formulated by mass: 4.5 parts of Span 83, 6 parts of glyceryl monostearate, 3 parts of calcium stearate, 1.5 parts of aluminum distearate, 20 parts of white vaseline, 10 parts of No. 26 white beeswax, 3 parts of paraffin, 12 parts of glycerin, 0.1 parts of methylparaben, 5 parts of wound healing components, and 35 parts of water.
3. A wound healing ointment as described in any one of claims 1-2, characterized in that, The preparation method of described wound healing ointment is as follows: S1, adding methylparaben to glycerol, heating and stirring until dissolved, to obtain a methylparaben glycerol solution for later use; S2, adding the wound healing component into water at a solid-liquid ratio of 1:6-8, stirring and dissolving to obtain an aqueous solution of the wound healing component for later use; S3, mixing the methylparaben glycerol solution obtained in step S1 and the wound healing component aqueous solution obtained in step S2, stirring, heating to 75-85° C., and keeping warm for 10-20 minutes to obtain an aqueous phase drug; S4, mixing Span 83, glyceryl monostearate, calcium stearate, aluminum distearate, white vaseline, No. 26 white beeswax, and paraffin, stirring, heating to 75-85° C., and keeping warm for 10-20 minutes to obtain an oil phase drug; S5. While stirring at 550-650 r / min, slowly add the water phase drug to the oil phase drug. After adding, stir at 1000-1400 r / min for 10-20 min, then at 150-250 r / min for 4-6 min. Cool to 35-45°C, and stir at 3000-4000 r / min for 2-4 min to obtain a wound healing ointment.
4. A wound healing ointment as claimed in claim 3, characterized in that, In the step S1, the temperature is heated to 65-75°C.
5. A wound healing ointment as claimed in claim 3, characterized in that, In the step S2, the wound healing component is added into water at a solid-liquid ratio of 1:7 and stirred to dissolve, thereby obtaining an aqueous solution of the wound healing component.
6. A wound healing ointment as claimed in claim 3, characterized in that, In step S5, the flow rate of slowly adding the aqueous phase drug to the oil phase drug is 25-35 ml / min.
